Cochrane Summaries

Trusted evidence. Informed decisions. Better health.

Additional chemotherapy with doxorubicin marginally improves tumour response but increases side effects with no improvement in survival

Bramwell V, Anderson D, Charette M
Published Online: 
8 October 2008

Doxorubicin is commonly used as palliative chemotherapy for patients with advanced or metastatic soft tissue sarcoma (cancer of muscle/tendon/fat/blood vessel). This review was conducted to find out if combining doxorubicin with other drugs is more effective than doxorubicin alone. Eight studies were considered together, which showed if combination chemotherapy is given: (1) tumour shrinkage was marginally better than in patients treated with doxorubicin alone; (2) survival was no different; and (3) side effects were worse than for patients treated with doxorubicin alone

This record should be cited as: 
Bramwell V, Anderson D, Charette M, Sarcoma Disease Site Group . Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD003293. DOI: 10.1002/14651858.CD003293
Assessed as up to date: 
29 September 2006
Health topics: